Replies to post #9779 on Opko Health Inc (OPK)

[Femto99]

BREAKING NEWS: @BioReference will now collaborate with employers nationally to provide highly accurate, testing services and on-site phlebotomy for #COVID19 antibodies. Learn how your organization can collaborate with BioReference for #antibodytesting. https://t.co/VdUGT6qEp3 https://t.co/gWeYsVbtO9

BREAKING NEWS: @BioReference will now collaborate with employers nationally to provide highly accurate, testing services and on-site phlebotomy for #COVID19 antibodies. Learn how your organization can collaborate with BioReference for #antibodytesting. https://t.co/VdUGT6qEp3 pic.twitter.com/gWeYsVbtO9

— BioReference Laboratories (@BioReference) May 15, 2020

[Femto99]

First time Friday it is actually going to close above strike price. Very bullish sign.

[Femto99]

8k https://www.opko.com/investors/sec-filings
ITEM 1.01.

Entry into a Material Definitive Agreement.
On May 12, 2020, OPKO Health, Inc. (“OPKO”) entered into an amendment (the “Amendment”) to that certain Development, Commercialization License Agreement, dated December 13, 2014 (the “Original License Agreement”), by and among OPKO, OPKO Ireland Ltd. (“OPKO Ireland”, and together with OPKO, the “Company”), and Pfizer, Inc. (“Pfizer”) for the Company’s long-acting human growth hormone product (hGH-CTP) for the treatment of growth hormone deficiency (GHD) and growth failure in children born small for gestational age (“PSGA”).

Under the terms of the Amendment, effective January 1, 2020, OPKO and Pfizer have agreed to share equally all costs for the remaining development of hGH-CTP for pediatric GHD (“PGHD”), including manufacturing costs and post-marketing studies. In addition, the parties updated and amended the Development Plan and Development Budget under the Original License Agreement. The milestone payments, royalties and profit share provisions under the Original License Agreement remain unchanged.

Pursuant to the Amendment, the parties have also agreed to work together to identify an additional pediatric indication for development other than PGHD on or before December 1, 2020. Development of the additional pediatric indication is subject to subsequent mutual agreement of the parties but, if agreed, all development costs for such indication shall be shared equally by the parties.

In addition, the parties also agreed on a process whereby Pfizer may, based on subsequent feedback from the US Food & Drug Administration, and in its reasonable discretion, submit a supplemental BLA for GHD in adults following receipt of regulatory approval of a biologics license application (BLA) for PGHD.